

Surjer Hashi Network
Independent Auditor's Report
and
Audited Financial Statements
For the year ended 30 June 2024

Independent Auditor's Report

To the Shareholders of Surjer Hashi Network

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of Surjer Hashi Network (SHN), which comprise the statement of financial position as at 30 June 2024, the statement of profit or loss and other comprehensive income, statement of changes in fund and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion, the accompanying financial statements give a true and fair view of the financial position of the Company as at 30 June 2024, and of its financial performance and its cash flows for the year then ended in accordance with the basis of accounting as described in note # 2.1 to the financial statements.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Bangladesh, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information

Management is responsible for the other information. The other information comprises all the information but does not include the financial statements and our auditor's report thereon. The other information are expected to be made available to us after the date of this auditor's report.

Our opinion on the financial statements does not cover other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and those Charged with Governance for the Financial Statements and Internal Controls

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the basis of accounting as described in notes # 2.1 to the financial statements, the Companies Act, 1994 and other applicable laws and regulations and for such



internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. The Companies Act, 1994 require the Management to ensure effective internal audit, internal control and risk management functions of the Company.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.


Report on other Legal and Regulatory Requirements

We report that the financial statements comply with the Companies Act, 1994 and other applicable laws and regulations. We, as required by law, further report that:

- a) we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;
- b) in our opinion, proper books of account as required by law have been kept by the Company so far as it appeared from our examination of these books; and
- c) the statement of financial position and statement of profit or loss and other comprehensive income dealt with by the report are in agreement with the books of account and returns.

Dhaka,
18 DEC 2024

Signed for & on behalf of
ACNABIN
Chartered Accountants



Md. Moniruzzaman, FCA
Partner


ICAB Enrollment No. 787


DVC : 2412230787AS711282


SURJER HASHI NETWORK
(Registered under Section-28 of The Companies Act, 1994)
Statement of Financial Position
As at 30 June 2024

	Notes	30.06.2024 Taka	30.06.2023 Taka
Assets			
Non-Current Assets			
Property, plant and equipment	5	124,395,508	43,894,101
Current Assets			
Inventories	6	34,136,903	22,181,844
Trade receivables	7	-	-
Other receivables	8	8,520,302	10,335,106
Advance income tax	9	15,096,482	9,932,564
Advances, deposits and prepayments	10	12,990,978	6,300,369
Investment in FDR	11	357,790,128	322,805,658
Cash and bank balance	12	76,396,167	90,958,304
Total current assets		504,930,960	462,513,845
Total Assets		629,326,468	506,407,946
Funds and Liabilities			
Funds			
Revolving Drug Fund	13	240,837,723	212,650,721
General Fund	14	219,092,007	225,634,409
Fixed Assets Fund (Grants in-kinds)	15	59,915,477	-
Total Funds		519,845,207	438,285,130
Non-Current liabilities			
Borrowings from bank (Long-term portion)	16	4,183,143	5,424,224
Current Liabilities			
Trade payables	17	193,866	121,015
Accrued and other payables	18	74,000,975	40,953,929
Current portion of long-term loan	16	1,240,958	1,134,684
Other liabilities	19	9,846,473	5,762,773
Provision for income tax	20	20,015,846	14,726,191
Total Current Liabilities		105,298,118	62,698,592
Total Liabilities		109,481,261	68,122,816
Total Funds and Liabilities		629,326,468	506,407,946

The annexed notes from 1 to 30 form an integral part of these Financial Statements.


General Manager (Finance)


Managing Director


Director

This is the Statement of Financial Position referred to in our separate report of even date.

Dhaka,
18 DEC 2024

Signed for & on behalf of
ACNABIN
Chartered Accountants



Md. Moniruzzaman, FCA
Partner


ICAB Enrollment No. 787


SURJER HASHI NETWORK
(Registered under Section-28 of The Companies Act, 1994)
Statement of Profit or Loss and Other Comprehensive Income
For the year ended 30 June 2024

	Notes	2023-2024 Taka	2022-2023 Taka
Revenue			
Milestones-based income from donor	21	150,665,309	165,766,940
Revenue from clinic services and pharmacy		554,023,119	547,369,493
		704,688,428	713,136,433
Cost of goods sold /services	22	672,309,783	680,933,826
Gross profit		32,378,645	32,202,607
Less: General and administrative expenses	24	174,775,665	137,247,875
Operating loss for the year		(142,397,020)	(105,045,268)
Donors' Contribution:			
Reimbursement by Donor	25	-	55,742,895
Grants from MoHFW/GoB	26	150,000,000	50,000,000
		7,602,980	697,627
Less: Finance expenses		956,637	98,732
Net operating profit for the year		6,646,343	598,895
Add: Non operating income	27		
Membership and subscription fees		22,000	22,000
Finance income		23,987,270	18,820,306
Other income		1,263,000	300
		25,272,270	18,842,606
Profit before tax		31,918,613	19,441,501
Less: Income tax expense		10,274,013	5,346,413
Net profit after tax		21,644,600	14,095,088
Add: Other comprehensive income		-	-
Total comprehensive income		21,644,600	14,095,088

The annexed notes from 1 to 30 form an integral part of these Financial Statements.


General Manager (Finance)



Managing Director


Director

This is the Statement of Profit or Loss and Other Comprehensive Income referred to in our separate report of even date.

Dhaka,
18 DEC 2024

Signed for & on behalf of
ACNABIN
Chartered Accountants


Md. Moniruzzaman, FCA
Partner

ICAB Enrollment No. 787

DVC: 2412230787AS711282

SURJER HASHI NETWORK
 (Registered under Section-28 of The Companies Act, 1994)
Statement of Changes in Fund
 For the year ended 30 June 2024

(Amount in Taka)

Particulars	Revolving Drug Fund (RDF)	General Fund	Fixed Assets Fund (Grants in-kind)	Total Fund
Balance as at 01 July 2023	212,650,721	225,634,409	-	438,285,130
Assets received from Donar	-	-	75,615,772	75,615,772
Depreciation during the year	-	-	(15,700,295)	(15,700,295)
Net profit after tax for the year	-	21,644,600	-	21,644,600
Gross profit from pharmacy sale	28,187,002	(28,187,002)	-	-
Balance as at 30 June 2024	240,837,723	219,092,007	59,915,477	519,845,207

Statement of Changes in Fund
 For the year ended 30 June 2023

Particulars	Revolving Drug Fund (RDF)	General Fund	Total Fund
Balance as at 01 July 2022	189,171,208	278,121,272	467,292,480
Prior year adjustment regarding Trade Receivable	-	(43,102,438)	(43,102,438)
Net profit after tax for the year	-	14,095,088	14,095,088
Gross profit from pharmacy sale	23,479,513	(23,479,513)	-
Balance as at 30 June 2023	212,650,721	225,634,409	438,285,130

The annexed notes from 1 to 30 form an integral part of these Financial Statements.

Dhaka,
 18 DEC 2024


 General Manager (Finance)


 Managing Director


 Director

SURJER HASHI NETWORK
(Registered under Section-28 of The Companies Act, 1994)
Statement of Cash Flows
For the year ended 30 June 2024

	2023-2024 Taka	2022-2023 Taka
A. Cash flows from operating activities		
Net profit before tax	31,918,613	19,441,501
Add: Items not involving in movement of cash:		
Depreciation	16,067,902	8,152,758
Operating profit before changes in working capital	47,986,515	27,594,259
Changes in working capital:		
Increase in inventory	(11,955,058)	(1,821,690)
Decrease in trade receivables	-	132,002,297
Decrease/(increase) in other receivables	1,814,804	(2,095,027)
Increase in advances, deposits and prepayments	(6,690,609)	(1,524,836)
Increase/ (decrease)in trade payables	72,851	(101,677)
Increase in other liabilities	4,083,699	5,256,267
Increase/(decrease) in accrued and other payables	33,047,046	(38,586,521)
Tax paid during the year	(10,148,276)	(8,525,584)
Net cash flow from operating activities	58,210,972	112,197,488
B. Cash flows from investing activities:		
Acquisition of property, plant and equipment	(36,653,832)	(26,968,539)
Short-term investments in FDR	(34,984,470)	(67,299,458)
Net cash used in investing activities	(71,638,302)	(94,267,997)
C. Cash flows from financing activities		
Borrowings from bank	-	6,740,000
Repayment of bank loan	(1,134,807)	(181,092)
Net cash (used in)/flow from financing activities	(1,134,807)	6,558,908
D. Net (used in)/increase in cash and bank balance (A+B+C)	(14,562,137)	24,488,399
E. Effect of changes in foreign currency	-	-
F. Opening cash and bank balance	90,958,304	66,469,905
G. Closing cash and bank balance (D+E+F)	76,396,167	90,958,304


The annexed notes from 1 to 30 form an integral part of these Financial Statements.

Dhaka,

18 DEC 2024


General Manager (Finance)


Managing Director


Director

SURJER HASHI NETWORK
(Registered under Section-28 of The Companies Act, 1994)

Notes to the financial statements
As at and for the year ended 30 June 2024

1. Background of the Company

1.1 Incorporation

Surjer Hashi Network (SHN) incorporated under Section 28 of the Companies Act 1994 as a not-for-profit Organization vide Certificate of Incorporation No. TO 959/2018 dated 18 April 2018. Company also obtained a license # 07/2018 dated 10 April 2018 from Ministry of Commerce as a Trade Organization (TO).

The registered office of the Company is located at Abedin Tower (6th Floor), Plot-35, Banani C/A, Road-17, Dhaka-1213, Bangladesh.

1.2 Objectives of the Company

Being a not-for-profit company, Surjer Hashi Network has been set up to facilitate the delivery of essential healthcare services in order to improve the health of people throughout Bangladesh especially the poor and underserved to support the national commitment of Bangladesh government to universal health coverage. SHN also aims at delivering healthcare programs and services in collaboration and coordination with partners who share the similar objectives and supports institution building and the expansion of existing institutional capacity aimed to improve access to quality healthcare for the poor.

1.3 Activities of the Company

The Company provides maternity and child health care services through outdoor patient and in-patient facilities by the 134 clinics. These activities (services) were initiated by earlier projects of USAID and the same functions are continued under this company. Currently, the Company is operating under the sustainability modality and generating the revenue from pharmacies and contractual services to the Advancing Universal Health Coverage (AUHC) project of Chemonics International Inc under cost-to-cost mechanism/fixed to mechanism.

1.4 Board Members

1.4.1 Following are the Members of the Company who have subscribed in the Memorandum of the Company.

SL	Name of members	Designation
1	Mr. Muhammad Ali	Member
2	Mr. Mainuddin M. Reza	Member
3	Dr. Mihir Kanti Majumder	Member
4	Mr. A.K.M. Aftabul Islam	Member
5	Mrs. Rupali Haque Chowdhury	Member
6	Dr. Abu Jamil Faisel	Member
7	Mr. Abbas Uddin Bhuiya	Member
8	Prof. Rubina Hamid	Member
9	Prof. Syed Abdul Hamid	Member

As per decision in General Meeting dated 12 July 2018, Dr. Halida Hanum Akhter has resigned. Another Board Director, Dr. Jahangir Hossain has died on May 2019 which has been confirmed in 9th Board Meeting dated 7 August 2019. All these have been ratified in 1st Annual General Meeting (AGM) dated 22 December 2019. Dr. Zerina Rahman Khan voluntarily resigned in 18th Board Meeting dated 10 December 2020 which has been ratified in 2nd Annual General Meeting dated 29 December 2020.

1.4.2 Company Members

There are 13 Members of the Company who have contributed the membership fees to be a member of the Company.

SL	Name of members	Designation
1	Mr. Md. Ali Reza Khan	Member
2	Dr. M. Moslehuddin	Member
3	Mr. Md. Azmal Kabir	Member
4	Mr. Shafiqul Azam	Member
5	Ms. Mufaweza Khan	Member
6	Mr. Shamsuddin Ahmed	Member
7	Mr. Jafrul Hasan	Member
8	Mr. Humayun Kabir	Member
9	Ms. Mahmuda Akhter	Member



10	Mr. Tauhidur Rahman	Member
11	Mr. Waliul Islam	Member
12	Ms. Uzma Chowdhury	Member
13	Mr. Ali Hossain Hawlader	Member

1.5 Board of Directors

The affairs of the Company is vested with a Board of Directors (consisting of 9 directors including the Chairman).

SL	Name of members	Designation
1	Prof. Rubina Hamid	Chairman
2	Mr. Muhammed Ali	Director
3	Dr. Mihir Kanti Majumder	Director
4	Mr. A. K. M. Aftabul Islam	Director
5	Mrs. Rupali Haque Chowdhury	Director
6	Dr. Abu Jamil Faisel	Director
7	Mr. Abbas Uddin Bhuiya	Director
8	Mr. Mainuddin M. Reza	Director
9	Prof. Syed Abdul Hamid	Director
10	Ms. Shaila Purvin	Ex-Officio

2. Basis of preparation**2.1 Statement of compliance**

The financial statements have been prepared on going concern basis under the historical cost convention in accordance with the International Financial Reporting Standards (IFRSs) and International Accounting Standards (IASs), the Companies Act 1994, sub-contract agreement and other laws and regulations applicable in Bangladesh.

2.2 Components of financial statements

The presentation of financial statements comprises of:

- i) Statement of financial position;
- ii) Statement of profit or loss and other comprehensive income;
- iii) Statement of changes in fund;
- iv) Statement of cash flows; and
- v) Notes to the financial statements.

2.3 Reporting period

These financial statements cover one year from 01 July to 30 June of a financial year.

2.4 Use of estimates and judgments

The preparation of financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revision to accounting estimates is recognized in the year in which the estimate is revised if the revision affects only that year, or in the year of revision and future periods if the revision affects both current and future periods.

Information about significant areas of estimation, uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amount recognized in the financial statements are described in the following notes:

Note: 5 Property, plant and equipment (useful life of depreciable assets)

Note: 20 Provision for current year income tax expense

2.5 Going concern

As per IAS 1: Presentation of Financial Statements, a company is required to make assessment at the end of each year to assess its capability to continue as going concern. Management of the company makes such assessment each year. The company has adequate resources to continue its operation for the foreseeable future and has wide coverage of its liabilities. For this reason, the management continues to adopt the going concern assumption while preparing the financial statements. The company provides and child health care services



through outdoor patients and in-patients facilities through 134 clinics. These activities were initiated by earlier projects of USAID and the same functions are continued under this company. Currently, the company is operating under the sustainability modality and generating the revenue from pharmacy and contractual services to the AUHC project of Chemonics International Inc. under cost-to-cost mechanism. This Cost of No Fees subcontract SUB-650 between Surjer Hashi Network and Chemonics International Inc. has been terminated on 31 July 2022. Subsequently, the Company entered into new contract namely Fixed Price Subcontract with Chemonics International Inc. vide subcontract no. AUHC-2023-007 started from 23 October 2022 to 30 November 2023. Besides, the Company has investment in financial instrument and the Ministry of Health and Family Welfare has given approval to provide financial assistance for the period from 2023 to 2025.

3. Summary of significant accounting policies

The accounting policies set out below has been applied consistently to all periods presented in these financial statements.

3.1 Property, plant and equipment

i. Recognition and measurement

These are capitalized at cost of acquisition and subsequently reported at cost less accumulated depreciation and impairment loss in compliance with the cost model of IAS 16 "Property Plant and Equipment". The cost of acquisition of an asset comprises its purchase price and any directly attributable cost of bringing the assets to its operating condition for its intended use inclusive of inward freight, duties and non-refundable taxes.

ii. Subsequent costs

Subsequent costs are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other costs are recognized in the statement of profit or loss and other comprehensive income as incurred.

iii. Depreciation

Depreciation is charged to amortize the cost of the assets, over their estimated useful lives, using straight line method in accordance with the provision of IAS 16: "Property, Plant and Equipment". Depreciation is charged on additions of the assets when they are ready to be used for commercial purpose and depreciation is charged until the month of disposal. Depreciation is provided at the following rates:

Name of assets	Rate
Furniture & fittings	10%
Medical equipment	20%
Computer & related equipment	25%
Office equipment	20%
Fire control system	20%
Vehicle	20%
Renovation and improvements	33.33%
Air conditioners	20%

iv. Gains or losses on disposal

An item of property, plant and equipment is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss on derecognition of an item of property, plant and equipment is determined as the difference between the net disposal proceeds and the carrying amount of the asset and is recognized in the statement of profit or loss and other comprehensive income.

3.2 Cash and bank balance

Cash and bank balance consists of cash in hand and at bank which are held and available for use by the company without any restriction.

3.3 Advances, deposits and prepayments

Advances are initially measured at cost. After initial recognition advances are carried at cost less deductions or adjustments. Deposits are measured at payment value. Prepayments are initially measured at cost. After initial recognition prepayments are carried at cost less charges to statement of profit or loss and other comprehensive income.

3.4 Trade receivables

Trade receivable are amounts due from AUHC regarding cost to cost and subcontract services provided in the ordinary course of business under programmed income. Trade receivable are recognized initially at fair value and subsequently measured at carrying amount less the amount collected from receivables and bad debts charged during the period.



**3.5 Other receivables**

Other receivables comprise with receivables from different customer under revenue contract agreement, membership fees and interest on FDR.

3.6 Inventories

Inventories are carried at the lower of cost and net realizable value as prescribed by IAS 2: Inventories. Cost is determined using weighted average method. The cost of inventories comprises of all costs of purchase, costs of conversion and other costs incurred in the normal course of business in bringing the inventories to their present location and condition. Costs of conversion include all direct costs excluding interest expense. Net realizable value is based on estimated selling price less any further costs expected to be incurred to make the sale.

3.7 Funds**3.7.1 Revolving Drug Fund (RDF)**

The revolving drug fund represents the cumulative earnings/surplus of pharmaceutical business segments. This fund has been operated on a revolving basis under the full control and ownership of the Company.

3.7.2 General Fund

General fund represents cumulative surplus/balances from P&L Accounts other than pharmaceutical business.

3.8 Provisions

Provision is recognized in the statement of financial position as per IAS 37 when the company has a legal or constructive obligation as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Provision is ordinarily measured at the best estimate of the expenditure required to settle the present obligation at the date of statement of financial position. Where the effect of time value of money is material, the amount of provision is measured at the present value of the expenditures expected to be required to settle the obligation.

3.9 Income tax expense

SHN has obtained approval from the Ministry of Commerce (License No. 7/2018 dated 10 April 2018) to be established as a not-for-profit Trade Organization under the Registrar of Joint Stock Companies and Firms (RJSCF). Objective of the Company is to re-invest the income/profit/accumulated profit in the charitable healthcare facilities. As per the approval of Ministry of Commerce and Memorandum of Association of the company, no profit is distributable to the company's members (shareholders) as dividend/share of profit. Since Surjer Hashi Network (SHN) is registered as a not-for-profit company with RJSCF under section 28 of the Companies Act 1994, income of the Company is not subject to income tax. As per 6th Schedule Part A Para 1(2), since the company's income is being applied for charitable purposes in Bangladesh during the income year and accumulated income will be applied for the same purposes in Bangladesh.

3.10 Revenue and income recognition

In accordance with the provisions of the IFRS-15: 'Revenue from Contract with Customers'; revenue from contract with customers represents the amount that reflects the considerations to which entity expects to be entitled in exchange for goods supplied and service provided to customers during the year. Revenue from contracts with customers is recognized in the statement of profit or loss and other comprehensive income when the performance obligation (supply of promised goods and services) is satisfied. Performance obligation is satisfied at a point in time when customer obtains the control of goods and services. Revenue is recognized as per 5 step model of IFRS 15 as follows:

- i. Identify the contract(s) with a customer;
- ii. Identify the performance obligations in the contract;
- iii. Determine the transaction price;
- iv. Allocate the transaction price to the performance obligations in the contract; and
- v. Recognize revenue when (or as) the entity satisfies a performance obligation.

Revenue from clinic services

At clinics, service income is generated from doctor's consultancy, child health, family planning and maternal health, lab services, registration fees and referral services and recorded as income at prescribed rate when the service is provided.

Revenue from pharmacy

Revenue from pharmacy includes the sale of medicines, vaccines, commodities and contraceptives which is recorded as revenue when it is earned that is at the point of sales.

**Subscription and membership fee**

SHN receives annual subscription and membership fee from their members. Annual subscription and membership fee are recognized when it is earned or becomes due.

Finance income

The Company recognized interest income as income when it is earned from bank interest on Fixed Deposit Receipt (FDR).

Revenue from Chemonics International Inc.

The Surjer Hashi Network will support AUHC toward the achievement of its objectives through its commitment to provide quality, customer-driven and affordable health services in a sustainable manner through its network of health clinics throughout the Bangladesh. The Surjer Hashi Network shall submit deliverables to AUHC as described in the contract and recognize revenue.

Grants from MoHFW/GoB

The Ministry of Health and Family Welfare (MoHFW), Government of Bangladesh (GoB) has accorded the special grants on 06 September 2023 to the network to meet its operational expenditure for the financial 2023 - 2024. The grant has been accounted for when it is fully utilized.

Grants received in kind (Fixed Assets)

Pursuant to IAS-20: Government Grants, Fixed assets received during the year are initially recorded as liability under the head "Fixed Assets Fund (Grants in Kind)" at their book value/written down value. The "Fixed Assets Fund (Grants in kind)" is adjusted with the depreciation of fixed assets charged for a particular year and corresponding amount of depreciation is recognized as income for that period in which it so applied.

3.11 Employment retirement benefits**3.11.1 Gratuity**

Permanent staffs shall be entitled to gratuity after completion of 1 (one) year of continuous service with the Company and will be paid upon termination of employment contract with the Company. Gratuity is equivalent to one month's of basic pay of employees' last salary drawn for each completed/partial year of service. Current practice of the company is to pay the employees after completion of each quarter(s)/year(s) of service either in retirement or continuation.

3.11.2 Provident fund

Permanent staffs shall be entitled to provident fund after confirmation of services with the Company and such benefit will be paid upon separation of employment with the Company. Provident fund is equivalent to 10% of monthly of basic pay of employees.

The Company has introduced "SHN Employees' Provident Fund" in financial year 2020-2021 which has been approved by National Board of Revenue (NBR).

3.12 Financial liabilities

Financial liabilities are recognized initially on the transaction date at which the company becomes a party to the contractual provisions of the liability. The company derecognizes a financial liability when its contractual obligations are discharged or cancelled or expired. Financial liabilities include payable for expenses, liability for capital expenditure and other current liabilities.

3.13 Impairment**(a) Financial assets**

Trade receivable and other receivables are reviewed at each reporting date to determine whether there is any objective evidence of impairment. Financial assets are impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset and that the loss event had a negative effects on the estimated future cash flows of that asset, that can be estimated reliably. Objective evidence that financial assets are impaired can include default or delinquency by a debtor, indications that a debtor or issuer will enter bankruptcy etc.

(b) Non-financial assets

An asset is impaired when its carrying amount exceeds its recoverable amount. The company reviews at each reporting date whether there is any indication that an asset may be impaired. If any such indication exists, the company estimates the recoverable amount of the asset. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.

Carrying amount of the assets is reduced to its recoverable amount by recognizing an impairment loss if, and only if, the recoverable amount of the asset is less than its carrying amount. Impairment loss is recognized immediately in profit or loss and other comprehensive income, unless the asset is carried at revalued amount.

Any impairment loss of a revalued asset shall be treated as a revaluation decrease.

3.14 Foreign currency transactions

The financial statements are presented in Bangladeshi Taka (Tk./BDT), which is the company's functional currency. Transactions in foreign currencies are recorded in the books at the exchange rate prevailing on the date of the transaction. Assets and liabilities in foreign currencies as on the reporting date are converted into Bangladeshi taka at the closing rate if applicable. Exchange gain or loss is recognized in Statement of Profit or Loss and Other Comprehensive Income as per IAS 21: The Effects of Changes in Foreign Exchange Rates.

3.15 Statement of Cash flows

Statement of cash flows is prepared principally in accordance with IAS-7: Cash Flow Statement and the cash flows from operating activities are presented under indirect method. A reconciliation of net profit with cash flows from operating activities under indirect method is also given.

3.16 Events after the reporting period

Events after the reporting period that provide additional information about the company's position at the date of statement of financial position or those that indicate the going concern assumption is not appropriate are reflected in the financial statements. There are no material events that had occurred after the reporting period to the date of issue of these financial statements, which could affect the figures presented in the financial statements.

3.17 Comparative information

Comparative information has been disclosed in respect of year 2022-2023 for all numerical information of the financial statements and also the narrative and descriptive information when it is relevant for understanding of the current period's financial statements.

3.18 Related Party Disclosures

As per IAS 24 "Related Party Disclosures", a related party is a person or entity that is related to the entity (i.e. SHN) that is preparing its financial statements. Related party transaction is a transfer of resources, services, or obligations between a reporting entity and a related party, regardless of whether a price is charged as per IAS 24.

Related parties include the company's directors, key management personnel, associates, companies under common directorship etc. as per IAS 24 "Related Party Disclosures". All transactions involving related parties arising in the normal course of business are conducted at arm's length at normal commercial rates on the same terms and conditions as third party transactions using valuation modes, as admissible.

4. General

- i) All amounts in these financial statements have been rounded off to the nearest Taka.
- ii) Previous year balance has been rearranged where by necessary.

	Notes	30.06.2024 Taka	30.06.2023 Taka
5. Property, plant & equipment			
i. Cost (Self Funded)			
Opening Balance		64,308,502	37,339,963
Add: Addition during the year		36,653,832	26,968,539
		100,962,334	64,308,502
Accumulated depreciation			
Opening balance		20,414,401	12,261,643
Add: Charged during the year		16,067,902	8,152,758
		36,482,303	20,414,401
A. Written down value		64,480,031	43,894,101
ii. Cost (Grants in kind)			
Opening Balance		-	-
Add: Addition during the year		75,615,772	-
		75,615,772	-
Accumulated depreciation			
Opening balance		-	-
Add: Charged during the year		15,700,295	-
		15,700,295	-
B. Written down value		59,915,477	-
C. Written down value (A+B)	(Annexure: A)	124,395,508	43,894,101
6. Inventories			
Commodities		2,978,637	2,589,880
Medicines		20,263,034	14,248,398
Contraceptives		1,699,412	1,073,756
Vaccines		6,840,333	4,259,644
Newborn Baby Cloth		1,343,103	-
Consumer Goods		1,007,543	10,167
Sanitary Napkin		4,841	-
		34,136,903	22,181,844
7. Trade receivables			
Opening balance		-	175,104,735
Less: Prior year adjustments*		-	43,102,438
Adjusted opening balance		-	132,002,297
Add: Receivable for invoice raised under sub-contract	(Annexure: B)	150,665,309	221,509,835
Receivable for assets purchase from PI		-	50,608,594
Receivable for accrued expenses under sub-contract		-	-
		150,665,309	404,120,726
Less: Received under sub-contract	(Note- 7.1)	150,665,309	395,086,083
Bad debt expense	(Annexure: B)	-	9,034,643
		-	-

* Surjer Hashi Network has trade receivable with receivable for accrued expense under sub-contract to Chemonics International Inc. a project of AUHC. The excess trade receivable has erroneously been recognized in the early years of the sub-contract continued till last year. Therefore, the prior year adjustment of Tk. 43,102,438 has been made with the opening balance of trade receivable and correspondingly with the general fund by the same (Ref. Note-14).

7.1 Received under sub-contract			
Received during the year from AUHC	(Annexure: B)	150,665,309	395,086,083

Disclosure as per Schedule XI, Part I, Para (F) of the Companies Act 1994:

I. Debt considered good in respect of which the company is fully secured

Trade receivable have been stated at their nominal value. Trade receivables are accrued in the ordinary course of business. The entire amount of the receivables has been realized during the year and hence there was no balance at the reporting date.

	Notes	30.06.2024 Taka	30.06.2023 Taka
II. Debt considered good for which the company hold no security			
Part of the receivables are unsecured but considered good.			
		-	-
III. Debt due by directors or other officers of the company			
There is no such debtors due by or to directors or other officers of the Company.			
IV. Debt considered doubtful or bad			
		-	9,034,643
Management is considered the debts as bad debt amounting in Taka 9,034,643 in respect of trade receivable in the last year.			
V. The maximum amount due by directors or other officers of the company			
There are no such debt due in this respect as at 30 June 2024.			
		-	-
8. Other receivables			
Receivables for membership fees		10,000	10,000
Receivable from services	(Note- 8.1)	163,489	166,272
Interest receivable on FDR		8,346,813	10,158,834
		8,520,302	10,335,106
8.1 Receivable from services			
Bills receivable from service rendered		163,489	160,772
Bills receivable from medicine sold		-	5,500
		163,489	166,272
The aging of other receivables as at the statement of financial position date was:			
Less than 06 months		8,520,302	10,335,106
More than 06 months but less than 12 months		-	-
More than 12 months		-	-
		8,520,302	10,335,106
9. Advance income tax			
Opening balance		9,932,564	4,415,392
Add: Paid during the year		5,163,918	5,517,172
		15,096,482	9,932,564
10. Advances, deposits and prepayments			
Advances	(Note- 10.1)	1,511,413	154,235
Deposits	(Note- 10.2)	130,000	1,130,000
Prepayments	(Note- 10.3)	11,349,565	5,016,134
		12,990,978	6,300,369
10.1 Advances			
Advance given against travel		868,188	146,235
Advance given against program		643,225	8,000
		1,511,413	154,235
10.2 Deposits			
Aftabnagar clinic		-	1,000,000
Gazipur clinic		130,000	130,000
		130,000	1,130,000
10.3 Prepayments			
Advance rent - HQ		1,171,090	1,171,090
Advance rent- Clinics		10,178,475	3,845,044
		11,349,565	5,016,134
11. Investment in FDR			
Investment in FDR	(Annexure: C)	357,790,128	322,805,658
12. Cash and bank balance			
Cash in hand	(Note- 12.1)	3,864,502	4,479,480
Cash at bank	(Note- 12.2)	72,531,665	86,478,824
		76,396,167	90,958,304

Notes	30.06.2024 Taka	30.06.2023 Taka
12.1 Cash in hand		
Petty cash- HQ	80,000	40,000
Petty cash - Clinics	1,582,807	1,613,227
General cash service income- Clinics	1,530,986	2,232,440
General cash pharmacy- Clinics	670,709	593,813
	3,864,502	4,479,480
12.2 Cash at bank		
General bank account- HQ	2,664,608	854,873
Grants bank accounts- HQ	50,509	20,152,315
Service income bank account - HQ	39,122,340	33,744,683
Pharmacy bank account - HQ	1,106,411	5,798,562
	42,943,868	60,550,433
Program income bank accounts - Clinics	20,245,581	13,342,002
Pharmacy bank accounts - Clinics	9,342,216	12,586,389
	29,587,797	25,928,391
	72,531,665	86,478,824
<p>SHN maintains 274 bank accounts with Dutch Bangla Bank PLC. (DBBL) throughout the country and 1 bank account is maintained with Brac Bank PLC. At clinic level, there are 134 bank accounts for service income and 135 bank accounts for pharmacy and at SHN HQ level, 1 bank account to receive amount from customers (Chemonics International Inc.), 1 bank account for service income, 1 bank account for pharmacy and 3 bank accounts for HQ-others.</p>		
13. Revolving Drug Fund		
Opening balance	212,650,721	189,171,208
Add: Gross profit from pharmacy sale	28,187,002	23,479,513
	240,837,723	212,650,721
<p>RDF fund represents the cumulative earnings surplus/balances of pharmaceutical business.</p>		
14. General fund		
Opening balance	225,634,409	278,121,272
Less: Prior year adjustment	-	43,102,438
Adjusted opening balance	225,634,409	235,018,834
Add: Net profit after tax for the year	21,644,600	14,095,088
Less: Gross profit from pharmacy sale	28,187,002	23,479,513
	219,092,007	225,634,409
<p>General fund represents cumulative surplus/balances from Profit or Loss and Other Comprehensive Income of the company other than pharmaceutical business.</p>		
15. Fixed Assets Fund (Grants in-kinds)		
Opening balance	-	-
Add: Addition during the year	(Annexure: A) 75,615,772	-
	75,615,772	-
Less: Depreciation during the year	15,700,295	-
	59,915,477	-
16. Borrowings from bank		
Opening balance	6,558,908	6,740,000
Repayment of loan during the year	1,134,807	181,092
	5,424,101	6,558,908
Repayment of loan shall be made:		
Within one year	1,240,958	1,134,684
Two to five years	4,183,143	5,424,224
	5,424,101	6,558,908

The term loan facility was taken in April 2023 under "BAHON" scheme from Brac Bank PLC. at the rate of interest on FDR+2% p.a but not exceeding 9% p.a for a period of five years for the purchasing the motor vehicle for the company with collateral of FDRs amounting to 10 million maintaining with the same bank. The loan shall be repaid with equal sixty monthly installment over the next five years.

Notes	30.06.2024 Taka	30.06.2023 Taka
17. Trade payables		
Incepta Pharmaceuticals Limited	41,439	22,964
Aristorpharma Ltd	3,763	-
Nipro JMI Pharma Limited	10,476	-
SMC Enterprise Limited	12,055	-
Renata Pharmaceuticals Limited	26,016	26,016
Square pharmaceutical companies	33,606	31,055
Pharmacy Others Accounts Payable - Tradeable	66,511	40,980
	193,866	121,015
18. Accrued and other payables		
Salaries and wages	57,355,119	34,313,252
Allowance	35,000	155,554
General Administrative	1,149,159	555,339
Audit fee	529,000	480,000
Fees, honoraria, allowances	7,126,514	128,798
Rent expense and utilities	7,806,183	5,320,986
	74,000,975	40,953,929
19. Other Liabilities		
Payable for withholding tax	195,090	443,234
Advance subscription received from members	-	16,000
Education & Training Payable	28,822	-
Marketing & Promotional expense Payable	2,454,442	-
Payable for travel, transportation and per-diem	1,570,921	572,839
Payable for Medical and office equipment	5,597,198	4,730,700
	9,846,473	5,762,773
20. Provision for income tax		
Opening balance	14,726,191	12,388,190
Add: Provision made during the year	10,274,013	5,346,413
	25,000,204	17,734,603
Less: Payment made during the year	4,984,358	3,008,412
	20,015,846	14,726,191

Referring to the Note-1, being charitable no profit of the company is distributable to the company's members (shareholders) as dividend/share of profit according to the approval of Ministry of Commerce and Memorandum of Association of the company. Since Surjer Hashi Network (SHN) is registered as a not-for-profit company with RJSCF under section 28 of the Companies Act 1994 hence income of the Company is not subject to income tax.

As per 6th Schedule Part A Para 1(2), since the company's income is being applied for charitable purposes in Bangladesh during the income year and accumulated income will be applied for the same purposes in Bangladesh, such income shall not be included in the total income of the income year of the company for tax purposes.

Company also obtained an opinion dated on 27 November 2021 from an independent expert firm, J U Ahmed & Co. Chartered Accountants which stated that as a registered not-for-profit trade organization and voluntary social enterprise, the company is not subject to income tax.

However, the Deputy Commissioner of Taxes (DCT), Tax circle-24, Tax Zone-2 issued a notice dated 30 October 2022 for the income year 2020-21 to appear before the DCT with some explanations and documents on 22 November 2022. SHN has produced the requested explanations and documents before the DCT on that day and he asked for further explanations and documents on different occasions. Having reviewed the documents, DCT has assessed the tax liability of the company and claimed an amount of Tk. 32,40,163 to be paid as tax in respect of the year and hence the amount has been taken into account while making the provision for Tax in the current year.

	Notes	2023-2024 Taka	2022-2023 Taka
21. Revenue			
Milestones-based income from donor	(Annex-B)	150,665,309	165,766,940
Revenue from clinic services		431,726,841	447,113,101
Revenue from pharmacy		122,296,278	100,256,392
		704,688,428	713,136,433
<p>In the last year of AUHC's implementation, USAID has indicated a new direction for the relationship with SHN and hence SHN has entered into a fixed price agreement with Chemonics dated 23 October 2022 wherein some key milestones have been set related to the network's sustainability and the quality of its health services. The payment under this fixed price agreement was received based on achievement of certain milestones. Proportionate amount was awarded for proportionate achievements of certain milestones.</p>			
22. Cost of goods sold/Services			
Cost of clinic services	(Note- 22.1)	578,200,507	604,156,947
Cost of goods sold (pharmacy)	(Note- 22.2)	94,109,276	76,776,879
		672,309,783	680,933,826
22.1 Cost of clinic services			
Total expenses incurred during the year	(Note- 23)	752,976,172	741,404,822
Less: General and administrative expenses	(Note- 24)	174,775,665	137,247,875
		578,200,507	604,156,947
22.2 Cost of goods sold (pharmacy)			
Opening inventories		22,181,845	20,360,154
Add: Purchase during the year		106,064,334	78,598,570
		128,246,179	98,958,724
Less: Closing inventories		34,136,903	22,181,845
		94,109,276	76,776,879
23. Total expenses incurred during the year			
Salary & wages		383,076,979	371,816,720
Fees, honorarium, allowances		117,788,596	149,664,124
Travel, transportation and per-diem		23,251,690	18,568,246
Marketing & promotional expenses		10,264,667	-
Education and training		570,464	757,233
Rent and utilities expenses		101,007,982	87,525,665
Repair maintenance and other services		23,750,377	27,654,295
Supplies and stationaries		35,177,947	33,282,174
General administration expenses		8,508,248	8,574,043
Audit fee and professional fee		1,366,484	1,307,710
Uniform		162,710	238,503
Depreciation expense		16,067,902	8,152,758
Bank charge		432,286	-
Discount		31,549,840	24,828,708
Bad debt expenses		-	9,034,643
		752,976,172	741,404,822
24. General and administrative expenses			
Salary & wages		80,289,681	64,794,204
Fees, honorarium, allowances		1,880,471	3,894,937
Travel, transportation and per-diem		12,855,733	7,586,105
Marketing & promotional expenses		4,857,086	-
Education and training		562,617	702,027
Rent and utilities expenses		9,837,495	8,495,198
Repair maintenance and other services		7,713,862	4,659,232
Supplies and stationaries		3,477,291	1,152,586
General administration expenses		3,759,663	2,490,979
Audit fee and professional fee		1,357,894	1,456,498
Uniform		133,844	-
Depreciation expense		16,067,902	8,152,758
Bank charge		432,286	-
Bad debt expenses		-	9,034,643
Discount		31,549,840	24,828,708
		174,775,665	137,247,875

	Notes	2023-2024 Taka	2022-2023 Taka
25. Reimbursement by Donor			
Cost No Fee, Subcontract		-	55,742,895
Grants received in kind	(Note - 25.1)	-	-
		<u>-</u>	<u>55,742,895</u>
<p>SHN received reimbursement from donor (net of clinic service revenue) under clause B.3(d) of sub-contract during last year. The deficit balance of costs under the service contract is charged to Chemonics. In compliance with the terms of Cost No Fee, Subcontract (SUB-650), executed between Chemonics International Inc. (Contractor) and Surjer Hashi Network (SHN) for Advancing Universal Health Coverage (AUHC) project; the costs over the clinic service income are reimbursed by the Contractor to Subcontractor (SHN).</p>			
25.1 Grants received in kinds			
Received from grants		15,700,295	-
Depreciation charged on assets (Grants in kinds)	(Annexure - A)	<u>(15,700,295)</u>	<u>-</u>
		<u>-</u>	<u>-</u>
<p>Pursuant to IAS-20, income is recognized only when it equates to the expenditure hence the for utilization of the grants in kinds the income is recognized equates to the depreciation charged on the donated fixed assets for the year incurred for the company during the year.</p>			
26. Grants from MoHFW/GoB			
Grants from Ministry of Health and Family Welfare (MoHFW)		<u>150,000,000</u>	<u>50,000,000</u>
<p>The Ministry of Health and Family Welfare (MoHFW), Government of Bangladesh (GoB) has accorded the special grants on 14 September 2023 to the network to meet its operational expenditure for the financial 2023-24. The grant has been fully utilized as it was intended for.</p>			
27. Non operating income			
27.1 Membership and subscription fees			
Members annual subscription		<u>22,000</u>	<u>22,000</u>
<p>Each members of the company including the Board of Directors contributes Taka 1,000 to the company as an annual subscription.</p>			
27.2 Finance income			
Interest on fixed deposits receipts		<u>23,987,270</u>	<u>18,820,306</u>
27.3 Other income			
Other income		<u>1,263,000</u>	<u>300</u>
28. Number of employees			
Above Taka 3,000 per month		<u>1077</u>	<u>1033</u>
<p>There were 88 and 989 regular employees engagement in the SHN headquarters and clinics respectively at the end of June 2024.</p>			
29. Related party transactions			
<p>Except the following, the Company has no related party and there was no related party transactions during the year:</p>			
Nature of related party transactions			
Monthly honorarium of Chairman, Board of Directors		799,992	806,658
Honorarium of Board Members/Directors for Annual General Meeting,		608,879	633,327
Labor lawyer retainership fees - Advocate Jafrul Hasan, General		564,561	566,672
		<u>1,973,432</u>	<u>2,006,657</u>
<p>As per SHN Board approval, SHN Board Chairman receives Taka 60,000 (net of tax) as a monthly honorarium and each Board Directors/Company Members receives Taka 10,000 (net of tax) as an honorarium for attending each SHN Board/Subcommittee/Annual General meeting.</p>			
<p>As a labor lawyer Advocate Jafrul Hasan, General Member of the Company, was selected for providing professional services on labor related issues on a retainership basis. Since control of the Company is vested to and managed by the Board of Directors of the Company , there should not be any conflict of interest even though Advocate Jafrul Hasan has provided the professional services as a General Member of the company.</p>			
30. Other financial information			
<p>a) No. of clinics operated in 2024 and 2023 is 134.</p>			
<p>b) SHN Network level cost recovery in 2024 and 2023 is 68.30% and 69.7% respectively. These rates were calculated without considering the amount for the close-out clinics' rent and non-cash items.</p>			
<p>c) Clinic level cost recovery in 2024 and 2023 is 77.21% and 76.7% respectively. These rates were calculated without considering the amount for the close-out clinics' rent and non-cash items.</p>			
<p>d) Margin on RDF sales in 2024 and 2023 is 23% and 23% respectively. These rates were calculated considering the direct materials cost.</p>			



SURJER HASHI NETWORK
(Registered under Section-28 of The Companies Act, 1994)
Property, Plant & Equipment
As at 30 June 2024

(Amount in Taka)

Particulars	Cost			Rate (%)	Depreciation			Written down value as at 30 June 2024
	Balance as at 01 July 2023	Addition during the year	Disposal / Adjustment during the year		Balance as at 30 June 2024	Charged during the year	Disposal / Adjustment during the year	
Furniture & fittings	2,791,683	1,167,076	-	3,958,759	304,581	-	1,287,962	2,670,797
Medical equipment	42,716,168	17,983,986	-	60,700,154	9,766,368	-	27,787,810	32,912,344
Computer & related equipment	4,024,304	8,384,140	-	12,408,444	1,726,499	-	1,903,456	10,504,988
Office equipment	2,914,142	1,370,571	-	4,284,713	692,489	-	841,754	3,442,959
Other Equipment	141,804	298,820	-	440,624	41,206	-	54,360	386,264
Fire control system	2,110	2,800	-	4,910	749	-	1,184	3,726
Air conditioners	793,500	-	-	793,500	158,699	-	793,499	1
Vehicle	9,113,682	-	-	9,113,682	1,822,736	-	2,126,525	6,987,157
Renovation and Improvements	1,811,109	7,446,439	-	9,257,548	1,554,575	-	1,685,753	7,571,795
Total as at 30 June 2024	64,308,502	36,653,832	-	100,962,334	16,067,902	-	36,482,303	64,480,031
Total as at 30 June 2023	37,339,963	26,968,539	-	64,308,502	8,152,758	-	20,414,401	43,894,101

B. Grants In-kind Assets

Particulars	Cost			Rate (%)	Depreciation			Written down value as at 30 June 2024
	Balance as at 01 July 2023	Addition during the year	Disposal / Adjustment during the year		Balance as at 30 June 2024	Charged during the year	Disposal / Adjustment during the year	
Furniture & fittings	-	1,891,303	-	1,891,303	189,130	-	189,130	1,702,173
Medical equipment	-	48,428,616	-	48,428,616	9,685,723	-	9,685,723	38,742,893
Computer & related equipment	-	5,563,186	-	5,563,186	1,390,797	-	1,390,797	4,172,389
Office equipment	-	7,328,505	-	7,328,505	1,465,701	-	1,465,701	5,862,804
Other Equipment	-	6,086,093	-	6,086,093	1,217,219	-	1,217,219	4,868,874
Fire control system	-	234,401	-	234,401	46,880	-	46,880	187,521
Air conditioners	-	2,421,919	-	2,421,919	484,384	-	484,384	1,937,535
Renovation and Improvements	-	3,661,749	-	3,661,749	1,220,461	-	1,220,461	2,441,288
Total as at 30 June 2024	-	75,615,772	-	75,615,772	15,700,295	-	15,700,295	59,915,477
Total as at 30 June 2023	-	-	-	-	-	-	-	-

Surjer Hashi Network (SHN) has received assets from USAID as grants in kind till 30 June 2023. As the titles assets of these had not been transferred to SHN, they were not recognized in the books of accounts till 30 June 2023. As per Agreement No. AUHC-Transfer Agreement_2023_001 of June 14, 2023, USAID has transferred these assets' titles to SHN; consequently, these assets have been recognized at their book value of Tk. 75,615,772 and depreciation charged thereon according to the SHN's financial policy and procedures and correspondingly with the Fixed Assets Fund (Grants in-Kinds) by the same.





SURJER HASHI NETWORK

(Registered under Section-28 of The Companies Act, 1994)

Status of revenue from contractual services, received, receivable and bad debts
For the year ended 30 June 2024

SL.	Invoice date	Purpose	Costs period	(Amount in Taka)		
				2024 Invoice (Net) TK	2023 Received	2023 Bad debt
Opening Balance						
1	16-Aug-22	Salary and benefits July 22	July'22	-	159,774,790	5,707,083
2	25-Aug-22	Material Cost July 22	July'22	-	842,623	742,535
3	28-Nov-22	Material Cost and Final Settlement	July'22	-	65,908,415	2,573,249
1	22-Mar-23	Milestone # 1a	Q 1 (Oct'22 to Dec'22)	-	2,793,315	11,776
2	4-Apr-23	Milestone # 3a, 4a,5a,7a,9a,10a	Q 1 (Oct'22 to Dec'22)	-	28,890,000	-
3	11-Jun-23	Milestone # 2a and 8a	Q 1 (Oct'22 to Dec'22)	-	122,117,727	-
4	25-Jul-23	Milestone # 4	July-23	-	14,759,213	-
5	30-Aug-23	Milestone # 5	August-23	31,589,976	-	-
6	31-Oct-23	Milestone # 6	October-23	10,950,000	-	-
7	1-Nov-23	Milestone # 7	November-23	25,255,890	-	-
8	30-Nov-23	Milestone # 8	November-23	5,525,000	-	-
9	1-Jan-24	Milestone # 9	January-24	11,100,000	-	-
Grand Total				150,665,309	395,086,083	9,034,643





SURJER HASHI NETWORK
(Registered under Section-28 of The Companies Act, 1994)
Schedule of investment in FDR
As at 30 June 2024

Sl. No.	FDR No.	Institute Name	Date of Issue	Date of Renewal	Date of Maturity	Source of Fund	(Amount in Taka)	
							2023-2024	2022-2023
01	10552243941303	IDLC Finance Ltd.	02 July 2021	02 July 2023	02 July 2024	Pharmacy	35,618,347	33,743,700
02	10552243941305	IDLC Finance Ltd.	02 July 2021	02 July 2023	02 July 2024	Pharmacy	42,751,505	40,498,584
03	10552243941306	IDLC Finance Ltd.	12 May 2021	12 May 2024	27 May 2024	Pharmacy	-	55,543,212
04	1001251000024546	IPDC Finance Limited	10 October 2021	10 April 2024	10 October 2024	General Fund	695,796	650,162
05	710001110587	BDH Finance Corporation Ltd.	17 November 2021	17 November 2023	17 November 2023	Clinic Service	-	52,370,000
06	1710001115254	BDH Finance PLC	18 April 2023	18 April 2024	18 October 2024	Clinic Service	31,905,000	30,000,000
07	1001251000038835	IPDC Finance Limited	17 April 2023	17 April 2024	17 October 2024	Grants Fund	21,409,480	20,000,000
08	1001251000038833	IPDC Finance Limited	17 April 2023	17 April 2024	17 October 2024	Grants Fund	42,705,000	40,000,000
09	1001251000038836	IPDC Finance Limited	18 April 2023	17 April 2024	17 October 2024	Grants Fund	42,705,000	40,000,000
10	3055790550001	BRAC	02 April 2023	10 October 2024	02 April 2026	Clinic Service	10,000,000	10,000,000
11	1001251000052160	IPDC Finance Limited	30 June 2024	30 June 2024	30 December 2024	Clinic Service	30,000,000	-
12	1001251000052159	IPDC Finance Limited	30 June 2024	30 June 2024	30 September 2024	Clinic Service	20,000,000	-
13	1710001132577	BDH Finance PLC	30 June 2024	30 June 2024	30 December 2024	Clinic Service	20,000,000	-
14	1710001132572	BDH Finance PLC	30 June 2024	30 June 2024	30 December 2024	Clinic Service	20,000,000	-
15	1710001132570	BDH Finance PLC	30 June 2024	30 June 2024	30 December 2024	Clinic Service	10,000,000	-
16	10552243941309	IDLC Finance PLC	30 June 2024	30 June 2024	30 September 2024	Clinic Service	30,000,000	-
Total investment in FDR							357,790,128	322,805,658